Review
Food Science & Technology
A. M. Api, D. Belsito, D. Botelho, M. Bruze, G. A. Burton, J. Buschmann, M. A. Cancellieri, M. L. Dagli, M. Date, W. Dekant, C. Deodhar, A. D. Fryer, L. Jones, K. Joshi, M. Kumar, A. Lapczynski, M. Lavelle, I Lee, D. C. Liebler, H. Moustakas, M. Na, T. M. Penning, G. Ritacco, J. Romine, N. Sadekar, T. W. Schultz, D. Selechnik, F. Siddiqi, I. G. Sipes, G. Sullivan, Y. Thakkar, Y. Tokura
Summary: The assessment concluded that tetrahydro-6-(3-pentenyl)-2H-pyran-2-one does not exhibit genotoxicity and is below the Threshold of Toxicological Concern for repeated dose, reproductive, and local respiratory toxicity. There are no safety concerns for skin sensitization, phototoxicity, and environmental impact based on the current levels of use.
FOOD AND CHEMICAL TOXICOLOGY
(2022)
Article
Chemistry, Organic
Kanduru Lokesh, Nandarapu Kumarswamyreddy, Venkitasamy Kesavan
Summary: A metal-free oxa-Michael cascade reaction was developed for the synthesis of structurally diverse tetrahydro-dispiro[indolinone-3,2'-pyran-5',4''-pyrazolone] compounds with two tertiary and two quaternary stereocenters. The use of isatin-derived Morita-Baylis-Hillman alcohols as oxa-Michael donors provided a new and efficient approach for atom-economical transformations. The reaction exhibited excellent yields (up to 96%) and diastereoselectivities (up to > 20:1) within a shorter reaction time (15 min).
JOURNAL OF ORGANIC CHEMISTRY
(2022)
Article
Chemistry, Organic
Yan Shu, Shi-Yu Feng, Sheng-Qi Zhang, Xun Tian, Yun-Li Zhao, Hua-Juan Yang, Jia-Xin Wang, Gui-Ling He, Hao Zhou, Jia-Peng Wang, Le Cai, Zhong-Tao Ding
Summary: Ten new sesquiterpenes and two known polyketide-terpenoids were isolated from Bipolaris cynodontis DJWT-01. The structures of new compounds were elucidated by extensive spectroscopic analyses, derivative reactions, X-ray diffraction analysis, ECD data, and DP4+ calculations. Compounds 5, 7, and 11 exhibited proliferation-promoting effects on LPS-stimulated splenic lymphocytes in vitro. Compound 11 displayed potent cytotoxic activities against four cell lines and antimicrobial activity against Fusarium solani and F. oxysporum.
ORGANIC CHEMISTRY FRONTIERS
(2023)
Article
Chemistry, Multidisciplinary
Eva Vrbkova, Lada Sekerova, Eliska Vyskocilova, Martin Zapletal, Libor Cerveny
Summary: Several types of modified zeolite BETA38 with different iron loading were prepared and characterized. The introduction of iron significantly enhanced the catalytic activity of the materials, regardless of the amount of iron loading. The material with 1wt% Fe loading exhibited high conversion rates in various reactions. Particularly, the Fe loaded Beta 38 showed a significant catalytic effect in the Prins reaction of benzaldehyde with isoprenol.
RESEARCH ON CHEMICAL INTERMEDIATES
(2022)
Article
Chemistry, Applied
Candice L. Joe, Bahar Inankur, James Chadwick, Sha Lou, Jeffrey Nye, Neil A. Strotman, Albert J. DelMonte
Summary: A scalable synthesis of a key intermediate in the synthesis of an immuno-oncology asset was achieved with high yield and optimized processes. Through process improvement, process mass intensity was reduced and the number of unit operations decreased successfully.
ORGANIC PROCESS RESEARCH & DEVELOPMENT
(2021)
Article
Biochemistry & Molecular Biology
Xueli Tian, Rui Wang, Tingxuan Gu, Fayang Ma, Kyle Vaughn Laster, Xiang Li, Kangdong Liu, Mee-Hyun Lee, Zigang Dong
Summary: EGFR-TKI targeted therapy is effective for lung cancer patients with EGFR activating mutations, but drug resistance limits its efficacy. This study identified MEK1 and AKT1/2 activation as a major cause of resistance and found that costunolide, by targeting MEK1 and AKT1/2, could suppress resistant cell growth. The combination of osimertinib and costunolide showed synergistic or additive effects on tumor growth in osimertinib-resistant models. This study highlights a potential therapeutic strategy for osimertinib-resistant patients through dual targeting of MEK1 and AKT1/2 by costunolide.
Article
Chemistry, Medicinal
Asem Robinson Singh, Salam Asbin Singh, Thangjam Davis Singh, Naorem Tarundas Singh, Takhellambam Chanu Machathoibi, Okram Mukherjee Singh, Lisam Shanjukumar Singh
Summary: The leaf crude extract of Oroxylum indicum has been found to induce apoptosis and inhibit cell migration in prostate cancer cells. This research contributes to the understanding of the therapeutic potential of Oroxylum indicum.
Article
Chemistry, Physical
Mohammad Reza Poor Heravi, Parinaz Aghamohammadi, Esmail Vessally
Summary: An efficiently, magnetically retrievable Fe3O4@SiO2@NH2@Pd(OCOCH3)(2) nanoparticles were successfully synthesized and showed excellent catalytic performance in the one-pot multicomponent synthesis of biologically important compounds. The nanocatalyst is environmentally friendly, recyclable, fast-reacting, and high-yielding, making it attractive and economically viable for various organic reactions.
JOURNAL OF MOLECULAR STRUCTURE
(2022)
Article
Crystallography
Xiao-Feng Zhai, Shi-Hong Lin, Zhao-Zhao Zhou, Haixin Ding
Summary: This compound is monoclinic with the chemical formula C41H42O2Si. Its unit cell parameters are a = 14.1100(17) Å, b = 15.8352(19) Å, c = 16.644(2) Å, and β = 110.659(2) degrees. The volume is 3479.7(7) Å(3) and the structure contains four molecules.
ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES
(2023)
Article
Chemistry, Medicinal
Katsunori Tsuboi, Hidenori Kimura, Yoshie Nakatsuji, Momoe Kassai, Yoko Deai, Yoshiaki Isobe
Summary: This study identified a promising novel KMO inhibitor compound that increased neuroprotective kynurenic acid and showed potential as a drug candidate for treating Huntington's disease.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Oncology
Yuanyi Wang, Ting Zhang, Hongfei Du, Min Yang, Guangsu Xie, Teng Liu, Shihua Deng, Wei Yuan, Shuang He, Dongming Wu, Ying Xu
Summary: Lung cancer, particularly the adenocarcinoma subtype, is a highly prevalent and deadly disease. This study found that DPEP2 expression is significantly decreased in lung adenocarcinoma and is negatively associated with prognosis. DPEP2 overexpression inhibits epithelial-mesenchymal transition and cell metastasis, and reduces the expression of cancer stem cell transformation markers CD44 and CD133. Furthermore, DPEP2 improves sensitivity to cisplatin in lung adenocarcinoma. These findings highlight the importance of DPEP2 as a prognostic marker and a potential therapeutic target in lung adenocarcinoma.
Article
Biochemistry & Molecular Biology
Chella Perumal Palanisamy, Bo Cui, Hongxia Zhang, Selvaraj Jayaraman, Ponnulakshmi Rajagopal, Vishnu Priya Veeraraghavan
Summary: Compound 2, isolated from Euclea crispa, showed significant antioxidant activity and inhibited the growth of HO-8910 cells. It reduced the expression of proteins related to cell proliferation and metastasis while increasing the expression of proteins associated with cell death. Molecular docking analysis confirmed the binding affinity between compound 2 and CXCR4 and HER2.
BIOINORGANIC CHEMISTRY AND APPLICATIONS
(2022)
Article
Chemistry, Organic
A. A. Aghekyan, H. A. Panosyan
Summary: A series of novel derivatives of 4-spirotetrahydropyran-substituted dihydro- and tetrahydroisoquinolines with various different substituents in the first and second positions of the heterocyclic ring were prepared using a reaction method.
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY
(2022)
Article
Crystallography
Yucong Liu, Pingqiao Wang, Haixin Ding
Summary: This substance is monoclinic with the chemical formula C24H25BrClNO11. The lattice parameters are a = 28.914(5) angstrom, b = 7.9349(14) angstrom, c = 13.062(2) angstrom, and beta = 114.867(3) degrees.
ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES
(2022)
Article
Oncology
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, Timothy Price, Ralf D. Hofheinz, Bernard Nordlinger, Jean-Francois Daisne, Jos Janssens, Baruch Brenner, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian Fauth, Carla V. Hannig, John Zalcberg, Niall Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Karin Haustermans
Summary: The PETACC 6 trial investigated the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine in locally advanced rectal cancer, but found no improvement in efficacy and instead noted impaired tolerability and feasibility.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Filippo Pietrantonio, Giovanni Fuca, Daniele Rossini, Hans-Joachim Schmoll, Johanna C. Bendell, Federica Morano, Carlotta Antoniotti, Salvatore Corallo, Beatrice Borelli, Alessandra Raimondi, Federica Marmorino, Monica Niger, Alessandra Boccaccino, Gianluca Masi, Sara Lonardi, Luca Boni, Filippo De Braud, Maria Di Bartolomeo, Alfredo Falcone, Chiara Cremolini
Summary: The study compared FOLFOXIRI-bevacizumab with FOLFOX-panitumumab in left-sided RAS/BRAF wild-type mCRC and found no significant differences in outcomes, but a numerically superior survival outcome with FOLFOXIRI-bevacizumab. Chemotherapy-related adverse events were more frequent in the FOLFOXIRI-bevacizumab group, suggesting that while doublet chemotherapy plus anti-EGFRs remain the preferred treatment option, FOLFOXIRI-bevacizumab is a valuable alternative with potential better outcomes.
Meeting Abstract
Oncology
Josep Tabernero, Axel Grothey, Dirk Arnold, Michel Ducreux, Peter J. O'Dwyer, Maurizio Perdicchio, Alexander Abbas, Meghna Das Thakur, Natsumi Irahara, Anila Tahiri, Hans-Joachim Schmoll, Eric Van Cutsem
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Zhaohui Jin, Jesse G. Dixon, Hiral Parekh, Frank A. Sinicrope, Greg Yothers, Daniel G. Haller, Hans Schmoll, Aimery De Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Chris Twelves, Leonard B. Saltz, Naohiro Tomita, Takayuki Yoshino, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Thomas J. George, Qian Shi
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jun Yin, Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont, Eric Van Cutsem, Julien Taieb, Steven R. Alberts, Norman Wolmark, Hans-Joachim Schmoll, Leonard B. Saltz, Thomas J. George, Richard R. M. Goldberg, Rachel Kerr, Sara Lonardi, Takayuki Yoshino, Greg Yothers, Axel Grothey, Thierry Andre, Qian Shi
Summary: The study suggests that 3-year disease-free survival (DFS) can effectively replace 5-year overall survival (OS) as an endpoint in adjuvant chemotherapy colon cancer trials. Data shows that the association between DFS and OS strengthens as the follow-up duration of OS increases.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Zhaohui Jin, Jesse G. Dixon, Jack M. Fiskum, Hiral D. Parekh, Frank A. Sinicrope, Greg Yothers, Carmen J. Allegra, Norman Wolmark, Daniel Haller, Hans-Joachim Schmoll, Aimery de Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Christopher Tweleves, Michael O'Connell, Leonard B. Saltz, Sotaro Sadahiro, Charles D. Blanke, Naohiro Tomita, Jean-Francois Seitz, Charles Erlichman, Takayuki Yoshino, Takeharu Yamanaka, Silvia Marsoni, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Thomas J. George, Qian Shi
Summary: The study revealed that tumor biology is a more significant prognostic factor than age of onset in predicting the outcome of stage III colon cancer patients in the Adjuvant Colon Cancer ENdpoint database.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Meeting Abstract
Oncology
Zhaohui Jin, Jesse G. Dixon, Joleen M. Hubbard, Cathy Eng, Christopher Hanyoung Lieu, Jack Fiskum, Leonard B. Saltz, Herbert I. Hurwitz, Alan P. Venook, Hans-Joachim Schmoll, Charles S. Fuchs, J. Randolph Randolph Hecht, Chiara Cremolini, Eduardo Diaz-Rubio, Cornelis J. A. Punt, Niall C. Tebbutt, Volker Heinemann, Takayuki Yoshino, Aimery De Gramont, Qian Shi
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Richard M. Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Thierry Andre, Alberto F. Sobrero, Stuart M. Lichtman, Al B. Benson, Cornelis J. A. Punt, Tim Maughan, Tomasz Burzykowski, Dirkje Sommeijer, Everardo D. Saad, Qian Shi, Elisabeth Coart, Benoist Chibaudel, Miriam Koopman, Hans-Joachim Schmoll, Takayuki Yoshino, Julien Taieb, Niall C. Tebbutt, John Zalcberg, Josep Tabernero, Eric Van Cutsem, Alastair Matheson, Aimery de Gramont
Summary: Meta-analysis based on individual participant data is a powerful method for synthesizing evidence in clinical cancer research. The ARCAD database is a leader in using this methodology for methodological research, providing valuable insights into endpoint selection and clinical response assessment.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Andres J. M. Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P. Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosee, Mascia Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Roth, Claire Hemmaway, Peter W. Johnson, Kim M. Linton, Tobias Pukrop, Jettes Sonderskov Gorlov, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jense Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W. Krause, Hans J. Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jurgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus
Summary: This study reported the results of a trial involving 219 HIV-negative adults with primary CNS lymphoma (PCNSL). The results showed that MATRix significantly improves outcome in patients with PCNSL, with a long-term overall survival rate of 21%-56%. Addition of rituximab benefits patients, and the efficacy of whole-brain irradiation and autologous transplantation is comparable. Salvage therapy was ineffective. Importantly, MATRix and ASCT did not increase non-relapse mortality or second tumor incidence, and the side effects differed between WBRT and ASCT.
Meeting Abstract
Oncology
B. Chibaudel, M. Raeisi, T. Andre, G. Yothers, H. Schmoll, J. Bachet, R. Cohen, N. Wolmark, T. Yoshino, R. Goldberg, R. Kerr, S. Lonardi, T. George, E. Shacham-Shmueli, L. Sharara, Q. Shi, A. de Gramont
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
J. Tabernero, A. Grothey, D. Arnold, A. de Gramont, M. Ducreux, P. O'Dwyer, A. Tahiri, F. Gilberg, N. Irahara, H-J Schmoll, E. Van Cutsem
Summary: The addition of atezolizumab to FP/bevacizumab as first-line maintenance treatment after FOLFOX thorn bevacizumab induction did not improve efficacy outcomes for patients with BRAF wild-type metastatic colorectal cancer (mCRC).
Meeting Abstract
Oncology
C. Gallois, Q. Shi, J. Meyers, T. Andre, T. J. Iveson, A. F. Sobrero, S. Alberts, A. de Gramont, J. Meyerhardt, A. F. Shields, T. Georges, H. J. E-V. Schmoll, I. Souglakos, R. Kerr, S. Lonardi, G. Yothers, T. Yoshino, R. Goldberg, J. Taieb, D. Papamichael
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
Romain Cohen, Morteza Raeisi, Greg Yothers, Hans-Joachim Schmoll, Daniel G. Haller, Jean-Baptiste Bachet, Benoist Chibaudel, Norman Wolmark, Takayuki Yoshino, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham Shmueli, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Nadine J. McCleary, William S. Harmsen, Ellana Haakenstad, James M. Cleary, Jeffrey A. Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F. Sobrero, Eric Van Cutsem, Richard M. Goldberg, Marc Peeters, Josep Tabernero, Matt Seymour, Leonard B. Saltz, Bruce J. Giantonio, Dirk Arnold, Mace L. Rothenberg, Miriam Koopman, Hans-Joachim Schmoll, Henry C. Pitot, Paulo M. Hoff, Niall Tebbutt, Gianluca Masi, John Souglakos, Carsten Bokemeyer, Volker Heinemann, Takayuki Yoshino, Benoist Chibaudel, Aimery deGramont, Qian Shi, Stuart M. Lichtman
Summary: This study evaluated the time to progression and survival outcomes of second-line therapy for metastatic colorectal cancer in older adults aged 70 years and older compared with younger adults. It found that older adults were less likely to receive second-line therapy, but there was no statistically significant difference in survival outcomes between older and younger adults following second-line therapy.
JNCI CANCER SPECTRUM
(2022)
Article
Oncology
Jun Yin, Shaheenah Dawood, Romain Cohen, Jeff Meyers, John Zalcberg, Takayuki Yoshino, Matthew Seymour, Tim Maughan, Leonard Saltz, Eric Van Cutsem, Alan Venook, Hans-Joachim Schmoll, Richard Goldberg, Paulo Hoff, J. Randolph Hecht, Herbert Hurwitz, Cornelis Punt, Eduard Diaz Rubio, Miriam Koopman, Chiara Cremolini, Volker Heinemann, Christophe Tournigard, Carsten Bokemeyer, Charles Fuchs, Niall Tebbutt, John Souglakos, Jean-Yves Doulliard, Fairooz Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Qian Shi, Axel Grothey, Richard Adams
Summary: The study compared the outcomes of metastatic colorectal cancer patients from different regions in international randomized clinical trials. It found significant differences in overall survival among patients from different regions, with patients from the UK and Ireland showing lower survival rates compared to central Europe, southern Europe, and the USA. Possible factors contributing to this disparity include greater overall population representation, delayed diagnosis, and reduced availability of therapies.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)